arrow
H

Hideo Shigematsu

Research Institute for Radiation Biology and Medicine
H指数:20
被引数:1,295

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct risk profiles of heart failure and non-heart failure major adverse cardiovascular events among patients with early breast cancer: a competing-risk analysis

早期乳腺癌患者中心力衰竭与非心力衰竭主要心血管不良事件的不同风险特征:一项竞争风险分析

2026-09-150
OAAI
Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study☆

艾瑞布林与紫杉烷类作为HER2阳性局部晚期或转移性乳腺癌患者的一线化疗联合双HER2阻断治疗的比较:JBCRG-M06/EMERALD研究的最终生存结果☆

2026-07-210
OAAI
Lactobacillus reuteri lozenges and chemotherapy-induced oral mucositis in breast cancer outpatients: an exploratory randomized controlled trial

罗伊氏乳杆菌含片与化疗诱导的乳腺癌门诊患者口腔黏膜炎:一项探索性随机对照试验

2026-07-110
OA
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer

在JBCRG-M06/EMERALD研究中评估厄洛替尼联合双重HER2阻断在HER2阳性局部晚期或转移性乳腺癌中的生活质量评估

2026-06-100
PRE
Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

更正:原发灶与转移灶在药物疗效和预后方面的差异——一项对de novo IV期乳腺癌III期临床试验JCOG1017的探索性分析

2026-05-290
OAAI
Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trial

原发肿瘤切除可降低新诊断IV期乳腺癌的主要局部并发症风险:来自JCOG1017随机对照试验的二次数据分析

bjs
IF0
2026-05-010
PRE
Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study

将ypT0和ycN0联合用于ypN0临床淋巴结阳性乳腺癌新辅助化疗后的风险分层:一项多中心队列研究

2026-05-010
PRE
Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

原发性与转移部位在de novo IV期乳腺癌中药物疗效和预后的差异:一项JCOG1017 III期试验的探索性分析

2026-04-160
OAAI
Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trial
2026-01-220
OAAI
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110)

乳腺癌寡转移的转移导向疗法随机对照试验:OLIGAMI试验(JCOG2110)

2026-01-010
PRE
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)
2024-06-260
PRE
A Randomized Controlled Trial of Metastasisdirected Therapy for Oligometastases in Breast Cancer (OLIGAMI trial; JCOG2110)
2024-05-020
PRE
The Prognostic Impact of Adjuvant Endocrine Therapy by Age for Patients with Small Estrogen Receptor-Positive (ER plus ), Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer
2024-05-020
PRE